Formulations for small intestinal delivery of rsv and norovirus antigens
AssigneeVaxart, Inc.
InventorsGeorge Trager, Sean Tucker, Leesun Kim, Ciaran Scallan
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for generating an immunogenic response in humans. Further provided are methods for designing such compositions, e.g., for vaccines.
Claims20
A method for eliciting an immune response to a norovirus viral protein 1(VP1) in a human, the method comprising orally administering an immunogenic composition that elicits serum IgG and intestinal secretory IgA to the norovirus VP1 protein in the human, wherein the immunogenic composition comprises a tablet encompassed in an enteric coating, wherein (i) the tablet comprises a replication-incompetent adenovirus vector comprising a nucleic acid sequence encoding norovirus VP1 polypeptide and a nucleic acid sequence encoding a dsRNA adjuvant;
- and (ii) the enteric coating has a threshold pH of pH 5.9-6.1 that directs delivery and release of the adenovirus vector to the ileum of the human.
A method for eliciting an immune response to a norovirus viral protein 1 (VP1) in a human, the method comprising orally administering an immunogenic composition that elicits serum IgG and intestinal secretory IgA to the norovirus VP1 protein in the human, wherein the immunogenic composition comprises a tablet encompassed in an enteric coating comprising poly(methacrylic acid-co-methyl methacrylate) 1:1;
- and wherein the tablet is coated with 8-12% total solids weight gain of the enteric coating;
- and (i) the tablet comprises an E1/E3-deleted serotype 5 adenovirus vector comprising a nucleic acid sequence encoding norovirus VP1 polypeptide and a nucleic acid sequence encoding a TLR3 agonist;
- and (ii) the enteric coating has a threshold pH of pH 5.9-6.1 that directs delivery and release of the adenovirus vector to the ileum of the human.
Dependencies are inferred from the claim text.